Status: Not yet recruiting
VLA1553-403 Pregnancy Surveillance Study
This post-marketing, observational study evaluates pregnancy and infant outcomes up to 12 weeks after delivery among women who received the chikungunya vaccine (VLA1553) during pregnancy or within 30 days before their last menstrual period. A matched comparator cohort of pregnant women vaccinated with routine, pregnancy-recommended vaccines (not exposed to VLA1553) is included. No study procedures beyond routine care are performed.
Participants needed: 200
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Valneva Austria GmbHUpdated: Feb 17, 2026
Eligibility criteria
Women who have received the single dose of the VLA1553 vaccine during pregnancy... [+6]
Women who do not provide informed consent. [+1]